Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Arun Swarup Menawat is CEO at Firefly Neuroscience. OQRO lists 4 transactions filed with the SEC under this name, the latest on Sep 29, 2026, each linked to the official Form 4.
CEO
Disclosures on record
4
Companies involved
2
1 buy, median −20.5 pts vs S&P 500, beat it 0 of 1 time.
Average −20.5 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed May 20, 2025 to May 20, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Firefly NeuroscienceAIFF
2 disclosures · Oct 2025 – Sep 2026
Sep 25, 2026126Kdisclosed Sep 29
DetailsOfficial recordOct 28, 202574Kdisclosed Oct 30
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Profound MedicalPROF
2 disclosures · May 2025 · 2 bought
May 16, 2025Bought~$57Kdisclosed May 20
DetailsOfficial recordMay 15, 2025Bought~$43Kdisclosed May 20
DetailsOfficial recordAs of the latest filing on , Arun Swarup Menawat reported holding 587,089 shares of Profound Medical (PROF), worth about $4.36M at the last close of $7 (Nov 13, 2026). Holdings are also on file at Stereotaxis (STXS); together they are worth about $5.23M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Profound Medical PROF | 587,089 | 587K direct | $7 | $4.36M | May 16, 2025 |
| Stereotaxis STXS | 1,035,560 | 1.04M direct | $1 | $873K | Jul 1, 2026 |
Is this Arun Swarup Menawat’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Arun Swarup Menawat bought shares on the open market in 2025.
Arun Swarup Menawat reported 2 open-market purchases and 0 sales since 2025; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $100K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated May 16, 2025, Arun Swarup Menawat reported holding 587,089 shares of Profound Medical (PROF). At the last close of $7 on Nov 13, 2026, that is about $4.36M. This is the stake disclosed in filings, not a net worth.
Arun Swarup Menawat bought shares on the open market in 2025.
In SEC filings since 2025: the latest open-market purchase is from 2025; no open-market sale is on record.
Profound Medical (PROF), from 2025 to 2025: 2 purchases and 0 sales.
Arun Swarup Menawat reported 2 open-market purchases and 0 sales here, 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.